Company / CIK 0000064803
CVS HEALTH Corp
- Ticker
- CVS
- Size, estimated from filings
- Large cap ($10B – $200B)
- Insiders on file
- 22
- Members of Congress who traded it
- 6
- Federal contracts on record
- none matched
- Lobbying filings on record
- 27
- SEC filings
- EDGAR ↗
- Latest trade on record
- June 26, 2026
CVS HEALTH Corp (CVS) has 22 insiders on file who disclosed 71 transactions in the last 12 months (1 open-market buy, 27 sales, about $441.6M at reported prices), and 9 congressional trades in its stock are on record. No federal contract award that started in the last 180 days was found for a recipient with exactly this name, and 15 lobbying filings naming it as client report $865K in 2026.
CVS HEALTH Corp in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
BoughtSold
8 people account for the disclosed buying and selling in CVS HEALTH Corp over the last 12 months; the most active is ROBBINS LARRY with $317M.
Lobbying spend by quarter
How much has CVS HEALTH Corp reported spending on federal lobbying?
CVS HEALTH Corp reported $1.6M in lobbying over the last eight quarters, from filings matched by exact company name.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Finucane Anne A. | Director | 3 | 0 | 0 | October 16, 2026 |
| FARAH ROGER N | Director | 1 | 0 | 1 | October 13, 2026 |
| Newman Brian | Director | 3 | 0 | 1 | October 2, 2026 |
| AGUIRRE FERNANDO | Director | 4 | 0 | 2 | October 2, 2026 |
| Mahoney Michael F | Chairman, President & CEO | 2 | 0 | 0 | August 5, 2026 |
| KIRBY J SCOTT | Director | 2 | 0 | 0 | July 28, 2026 |
| Clark James David | SVP, Cont & Chief Acct Officer | 5 | 0 | 3 | June 29, 2026 |
| Compton-Phillips Amy | EVP, Chief Medical Officer | 3 | 0 | 1 | June 1, 2026 |
| ROBBINS LARRY | Director | 10 | 0 | 7 | May 21, 2026 |
| Gallina John E | Director | 2 | 0 | 0 | May 15, 2026 |
| Shulman Douglas H. | Director | 2 | 0 | 0 | May 15, 2026 |
| BROWN C DAVID II | Director | 2 | 0 | 0 | May 15, 2026 |
| DECOUDREAUX ALECIA A | Director | 2 | 0 | 0 | May 15, 2026 |
| SANSONE GUY P | Director | 2 | 0 | 0 | May 15, 2026 |
| Norwalk Leslie V | Director | 2 | 0 | 0 | May 15, 2026 |
| Balser Jeffrey R. | Director | 2 | 0 | 0 | May 15, 2026 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 5 | 0 | 3 | May 11, 2026 |
| Shah Prem S | EVP and Group President | 4 | 0 | 2 | April 2, 2026 |
| Nelson Steven H | EVP and President, Aetna | 4 | 1 | 1 | April 2, 2026 |
| Joyner J. David | President and CEO | 3 | 0 | 2 | April 2, 2026 |
| Khichi Samrat S. | EVP, CPO and General Counsel | 4 | 0 | 2 | April 2, 2026 |
| CAPOZZI HEIDI B | EVP and Chief People Officer | 7 | 3 | 2 | April 2, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Members of Congress who traded CVS
From periodic transaction reports that name the company's stock. Amounts are the sums of the ranges as filed. Every row is on the CVS page.
| Member | Seat | Trades | Bought | Sold | Range as filed | Latest |
|---|---|---|---|---|---|---|
| Lisa C. McClain | Representative (MI, District 9), Republican | 3 | 1 | 2 | $3,003–$45K | October 31, 2025 |
| Dwight Evans | Representative (PA, District 3), Democrat | 2 | 0 | 2 | $2,002–$30K | November 21, 2025 |
| Alan Armstrong | Senator (OK), Republican | 1 | 1 | 0 | $1,001–$15K | March 27, 2026 |
| John Boozman | Senator (AR), Republican | 1 | 1 | 0 | $1,001–$15K | January 29, 2026 |
| Val T. Hoyle | Representative (OR, District 4), Democrat | 1 | 0 | 1 | $1,001–$15K | September 23, 2025 |
| Tommy Tuberville | Senator (AL), Republican | 1 | 0 | 1 | $1,001–$15K | August 26, 2024 |
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clark James David | CVS | Sell F | June 26, 2026 | June 29, 2026 | 3d | 454 | $91 | $41K | Form 4 ↗ | ||
| Newman Brian | CVS | Sell F | May 31, 2026 | June 1, 2026 | 1d | 2,478 | $91 | $225K | Form 4 ↗ | ||
| Compton-Phillips Amy | CVS | Sell F | May 31, 2026 | June 1, 2026 | 1d | 7,618 | $91 | $693K | Form 4 ↗ | ||
| AGUIRRE FERNANDO | CVS | Sell D | May 21, 2026 | May 22, 2026 | 1d | 1,563 | $94 | $146K | Form 4 ↗ | ||
| AGUIRRE FERNANDO | CVS | Sell D | May 20, 2026 | May 22, 2026 | 2d | 30,437 | $94 | $2.9M | Form 4 ↗ | ||
| ROBBINS LARRY | CVS | Option / conversion S | May 21, 2026 | May 21, 2026 | 0d | 378,000 | $93 | $35.3M | indirectderivative | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 21, 2026 | May 21, 2026 | 0d | 370,462 | $93 | $34.6M | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 20, 2026 | May 21, 2026 | 1d | 800 | $96 | $77K | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 20, 2026 | May 21, 2026 | 1d | 66,881 | $96 | $6.4M | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 20, 2026 | May 21, 2026 | 1d | 152,691 | $95 | $14.5M | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 20, 2026 | May 21, 2026 | 1d | 797,628 | $93 | $74.6M | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 19, 2026 | May 21, 2026 | 2d | 151 | $95 | $14K | indirect | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Sell S | May 19, 2026 | May 21, 2026 | 2d | 1,983,387 | $94 | $187.3M | indirect | Form 4 ↗ | |
| Gallina John E | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,448 | $97 | $141K | derivative | Form 4 ↗ | |
| Mahoney Michael F | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,737 | $97 | $169K | derivative | Form 4 ↗ | |
| AGUIRRE FERNANDO | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,563 | $97 | $152K | Form 4 ↗ | ||
| Balser Jeffrey R. | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 2,058 | $97 | $200K | Form 4 ↗ | ||
| KIRBY J SCOTT | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,447 | $97 | $141K | Form 4 ↗ | ||
| Norwalk Leslie V | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,447 | $97 | $141K | Form 4 ↗ | ||
| SANSONE GUY P | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,447 | $97 | $141K | Form 4 ↗ | ||
| DECOUDREAUX ALECIA A | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,448 | $97 | $141K | derivative | Form 4 ↗ | |
| Finucane Anne A. | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,544 | $97 | $150K | derivative | Form 4 ↗ | |
| BROWN C DAVID II | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,544 | $97 | $150K | Form 4 ↗ | ||
| Shulman Douglas H. | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,448 | $97 | $141K | derivative | Form 4 ↗ | |
| ROBBINS LARRY | CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,930 | $97 | $187K | derivative | Form 4 ↗ | |
| Mandadi Tilak | CVS | Sell S | May 8, 2026 | May 11, 2026 | 3d | 69,551 | $90 | $6.2M | Form 4 ↗ | ||
| Shah Prem S | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 161,676 | $72 | $11.6M | derivative | Form 4 ↗ | |
| Shah Prem S | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 1,484 | $72 | $108K | Form 4 ↗ | ||
| Shah Prem S | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 25,062 | $72 | $1.8M | Form 4 ↗ | ||
| Newman Brian | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 125,748 | $72 | $9.0M | derivative | Form 4 ↗ | |
| Newman Brian | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 19,493 | $72 | $1.4M | Form 4 ↗ | ||
| Nelson Steven H | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 143,712 | $72 | $10.3M | derivative | Form 4 ↗ | |
| Nelson Steven H | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 2,432 | $72 | $176K | Form 4 ↗ | ||
| Nelson Steven H | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 22,277 | $72 | $1.6M | Form 4 ↗ | ||
| Mandadi Tilak | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 143,712 | $72 | $10.3M | derivative | Form 4 ↗ | |
| Mandadi Tilak | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 3,634 | $72 | $263K | Form 4 ↗ | ||
| Mandadi Tilak | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 22,277 | $72 | $1.6M | Form 4 ↗ | ||
| Khichi Samrat S. | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 80,838 | $72 | $5.8M | derivative | Form 4 ↗ | |
| Khichi Samrat S. | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 3,541 | $72 | $257K | Form 4 ↗ | ||
| Khichi Samrat S. | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 12,531 | $72 | $900K | Form 4 ↗ | ||
| Joyner J. David | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 8,029 | $72 | $582K | Form 4 ↗ | ||
| Joyner J. David | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 86,326 | $72 | $6.2M | Form 4 ↗ | ||
| Compton-Phillips Amy | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 35,928 | $72 | $2.6M | derivative | Form 4 ↗ | |
| Compton-Phillips Amy | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 5,569 | $72 | $400K | Form 4 ↗ | ||
| Clark James David | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 11,976 | $72 | $860K | derivative | Form 4 ↗ | |
| Clark James David | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 3,262 | $72 | $236K | Form 4 ↗ | ||
| Clark James David | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 11,138 | $72 | $800K | Form 4 ↗ | ||
| CAPOZZI HEIDI B | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 64,670 | $72 | $4.6M | derivative | Form 4 ↗ | |
| CAPOZZI HEIDI B | CVS | Sell F | April 1, 2026 | April 2, 2026 | 1d | 1,334 | $72 | $97K | Form 4 ↗ | ||
| CAPOZZI HEIDI B | CVS | Other A | March 31, 2026 | April 2, 2026 | 2d | 10,025 | $72 | $720K | Form 4 ↗ | ||
| Gallina John E | CVS | Other A | March 19, 2026 | March 20, 2026 | 1d | 582 | $72 | $42K | Form 4 ↗ | ||
| Khichi Samrat S. | CVS | Sell F | February 28, 2026 | March 2, 2026 | 2d | 7,886 | $80 | $628K | Form 4 ↗ | ||
| Joyner J. David | CVS | Sell F | February 28, 2026 | March 2, 2026 | 2d | 1,944 | $80 | $155K | Form 4 ↗ | ||
| Nelson Steven H | CVS | Buy P | January 23, 2025 | January 27, 2026 | 369d | 24 | $54 | $1,289 | lateindirect | Form 4 ↗ | |
| Shah Prem S | CVS | Sell F | January 1, 2026 | January 5, 2026 | 4d | 247 | $80 | $20K | Form 4 ↗ | ||
| Clark James David | CVS | Sell F | December 1, 2025 | December 2, 2025 | 1d | 220 | $79 | $17K | Form 4 ↗ | ||
| Mandadi Tilak | CVS | Sell F | November 30, 2025 | December 2, 2025 | 2d | 6,575 | $80 | $528K | Form 4 ↗ | ||
| FARAH ROGER N | CVS | Sell F | November 30, 2025 | December 2, 2025 | 2d | 9,748 | $80 | $783K | Form 4 ↗ | ||
| CAPOZZI HEIDI B | CVS | Sell F | November 30, 2025 | December 2, 2025 | 2d | 9,470 | $80 | $761K | Form 4 ↗ | ||
| Shulman Douglas H. | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | Form 4 ↗ | ||
| SANSONE GUY P | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | Form 4 ↗ | ||
| ROBBINS LARRY | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 2,203 | $76 | $167K | derivative | Form 4 ↗ | |
| Norwalk Leslie V | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | Form 4 ↗ | ||
| Mahoney Michael F | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 2,022 | $76 | $154K | derivative | Form 4 ↗ | |
| KIRBY J SCOTT | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | Form 4 ↗ | ||
| Finucane Anne A. | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,775 | $76 | $135K | derivative | Form 4 ↗ | |
| Finucane Anne A. | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 591 | $76 | $45K | Form 4 ↗ | ||
| DECOUDREAUX ALECIA A | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | derivative | Form 4 ↗ | |
| BROWN C DAVID II | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,775 | $76 | $135K | Form 4 ↗ | ||
| Balser Jeffrey R. | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,775 | $76 | $135K | Form 4 ↗ | ||
| AGUIRRE FERNANDO | CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,800 | $76 | $137K | Form 4 ↗ | ||
| CAPOZZI HEIDI B | CVS | Buy P | October 23, 2024 | October 14, 2025 | 356d | 35 | $57 | $1,990 | lateindirect | Form 4 ↗ | |
| CAPOZZI HEIDI B | CVS | Buy P | October 2, 2024 | October 14, 2025 | 377d | 10 | $62 | $622 | lateindirect | Form 4 ↗ | |
| CAPOZZI HEIDI B | CVS | Buy P | September 9, 2024 | October 14, 2025 | 400d | 35 | $56 | $1,976 | lateindirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "CVS HEALTH Corp". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
| Period | Registrant | Primary issue | Amount | Source |
|---|---|---|---|---|
| 2026 Q3 | CONTINENTAL STRATEGY, LLC | Health Issues | $105,000 | LDA ↗ |
| 2026 Q3 | ALSTON & BIRD LLP | Health Issues | $30,000 | LDA ↗ |
| 2026 Q2 | MICHAEL BEST STRATEGIES LLC | Pharmacy | $110,000 | LDA ↗ |
| 2026 Q2 | CONTINENTAL STRATEGY, LLC | Health Issues | $105,000 | LDA ↗ |
| 2026 Q2 | BOCKORNY GROUP, INC. | Pharmacy | $100,000 | LDA ↗ |
| 2026 Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | Pharmacy | $60,000 | LDA ↗ |
| 2026 Q2 | ALSTON & BIRD LLP | Health Issues | $20,000 | LDA ↗ |
| 2026 Q1 | CONTINENTAL STRATEGY, LLC | Health Issues | $105,000 | LDA ↗ |
| 2026 Q1 | BOCKORNY GROUP, INC. | Pharmacy | $100,000 | LDA ↗ |
| 2026 Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | Pharmacy | $60,000 | LDA ↗ |
| 2026 Q1 | MICHAEL BEST STRATEGIES LLC | Health Issues | $40,000 | LDA ↗ |
| 2026 Q1 | ALSTON & BIRD LLP | Health Issues | $30,000 | LDA ↗ |
| 2026 Q1 | MICHAEL BEST STRATEGIES LLC | Health Issues | — | LDA ↗ |
| 2026 Q1 | KLEIN/JOHNSON GROUP | — | — | LDA ↗ |
| 2026 Q1 | KEEFE STRATEGIES LLC FKA KEEFE SINGISER PARTNERS | — | — | LDA ↗ |
| 2025 Q4 | BOCKORNY GROUP, INC. | Pharmacy | $105,000 | LDA ↗ |
| 2025 Q4 | CONTINENTAL STRATEGY, LLC | Health Issues | $105,000 | LDA ↗ |
| 2025 Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | Pharmacy | $60,000 | LDA ↗ |
| 2025 Q4 | KLEIN/JOHNSON GROUP | Labor Issues/Antitrust/Workplace | $50,000 | LDA ↗ |
| 2025 Q4 | KEEFE STRATEGIES LLC FKA KEEFE SINGISER PARTNERS | Health Issues | $30,000 | LDA ↗ |
| 2025 Q4 | ALSTON & BIRD LLP | Health Issues | $30,000 | LDA ↗ |
| 2025 Q3 | CONTINENTAL STRATEGY, LLC | Health Issues | $105,000 | LDA ↗ |
| 2025 Q3 | BOCKORNY GROUP, INC. | Pharmacy | $105,000 | LDA ↗ |
| 2025 Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | Pharmacy | $60,000 | LDA ↗ |
| 2025 Q3 | KLEIN/JOHNSON GROUP | Labor Issues/Antitrust/Workplace | $50,000 | LDA ↗ |
| 2025 Q3 | KEEFE STRATEGIES LLC FKA KEEFE SINGISER PARTNERS | Health Issues | $30,000 | LDA ↗ |
| 2025 Q3 | ALSTON & BIRD LLP | Health Issues | $30,000 | LDA ↗ |
Related companies
Companies whose stock was traded by the same people who traded CVS, by number of filers in common. It shows overlap in public filings and nothing else.
- MICROSOFT CORP MSFT 6 filers in common
- NETFLIX INC NFLX 5 filers in common
- NVIDIA CORP NVDA 5 filers in common
- Alphabet Inc. GOOGL 5 filers in common
- JOHNSON & JOHNSON JNJ 5 filers in common
- PayPal Holdings, Inc. PYPL 5 filers in common
- Apple Inc. AAPL 5 filers in common
- BOSTON SCIENTIFIC CORP BSX 5 filers in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Lobbying disclosure reports Reports are due about 20 days after each quarter ends.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| House Clerk, periodic transaction reports | 4 | 6 | October 10, 2025 | May 15, 2026 | House Clerk search |
| Senate eFD, periodic transaction reports | 3 | 3 | February 15, 2026 | August 5, 2026 | Senate eFD search |
| SEC EDGAR, Form 4 | 48 | 74 | October 14, 2025 | June 29, 2026 | Form 4 list on EDGAR |
| Lobbying disclosure filings | 27 filings | — | — | — | LDA.gov search |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.